Prostate News and Research

RSS
Study evaluates CaP risk among finasteride users

Study evaluates CaP risk among finasteride users

Prostate cancer treatment decisions can be complicated

Prostate cancer treatment decisions can be complicated

Long-term survival probability in men with clinically localized prostate cancer

Long-term survival probability in men with clinically localized prostate cancer

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

Chemicals in cruciferous vegetables may provide cancer-fighting benefit

Chemicals in cruciferous vegetables may provide cancer-fighting benefit

Aspirin may modestly reduce cancer risk

Aspirin may modestly reduce cancer risk

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Scientists tackle cancer with different approaches

Scientists tackle cancer with different approaches

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Clioquinol shows promise in fighting cancer

Clioquinol shows promise in fighting cancer

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Selenium as therapy for prostate cancer

Selenium as therapy for prostate cancer

Side-effects of treatment for localized prostate cancer

Side-effects of treatment for localized prostate cancer

Lilly and AACR tackle cancer together

Lilly and AACR tackle cancer together

FDA accepts Satraplatin NDA for priority review

FDA accepts Satraplatin NDA for priority review

FDA accepts GPC Biotech's Satraplatin NDA

FDA accepts GPC Biotech's Satraplatin NDA

Biomira selects PX-866 as clinical development candidate

Biomira selects PX-866 as clinical development candidate

Snake venom toxin as a treatment for prostate cancer

Snake venom toxin as a treatment for prostate cancer

Report on radical prostatectomy for octogenarians

Report on radical prostatectomy for octogenarians

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.